Leading fund manager Karst Peak Capital has secured a significant interest in a little-known Aussie pharmaceuticals research company, following the significant success they experienced with a large holding of Avita Medical. Originally based in Hong Kong but now also with an office in Sydney, Karst’s investment focus includes the healthcare, biotech and pharmaceuticals industry which
Read More
Working in conjunction with the CSIRO, Anatara Lifesciences (ASX: ANR) has received ethics approval to apply their diet supplement 3FDC to a new area of medicine, seeking to evaluate the compound’s effects in adults with moderate anxiety, stress and depression. 3FDC is one of the constituents of Anatara’s flagship supplement (GaRP) intended for the treatment
Read More
Aussie pharmaceuticals company Acrux (ASX: ACR) is quickly making inroads through the lucrative American healthcare system with regulatory approval granted for their generic equivalent of a common testosterone topical solution which generates more than $25 million annually. Approval was granted from the Food and Drug administration for Acrux’s gel following their submission in August 2018
Read More
Leading pharmaceuticals company CLINUVEL (ASX: CUV) is set to commence human trials using the drug afamelanotide to dissolve or remove underlying blood clots in the brain that cause arterial ischaemic stroke (AIS) which accounts for 85% of the 15 million strokes suffered worldwide each year. Current stroke therapies are reliant on early intervention to restore
Read More
As fears over the coronavirus outbreak continue to spread, health and nutritional product manufacturer Eagle Health (ASX: EHH) is set to diversify their distribution channels by entering a collaborative agreement with Amka Products which has a continental footprint throughout Africa. The agreement will see AMKA, a market leader for manufacturing and distribution of health products
Read More
Australian cannabis pharmaceuticals company THC Global (ASX: THC) is one major step closer to their ‘Farm to Pharma’ strategy, having been granted a Manufacture Permit from the Australian Office of Drug Control for their facility in Southport, Queensland. By securing the permit, THC Global will immediately commence production of medicinal cannabis products which have been
Read More